… of lung cancer from the Norwegian Lung Cancer Biobank study (NLCB registry study), we
identified a total of 1852 cases of lung cancer that were evaluated for inclusion into our study. …

… and increased 5-10-year survival rates by 5-10% … agents in lung cancer showed that they
actually impaired survival, … that newer chemotherapeutic agents prolong survival and alleviate …

… the potential to lengthen survival, particularly in patients with advanced nonsmall-cell lung
cancer. This review summarizes the literature on potential survival benefits of palliative care …

The survival benefit of combination chemotherapy to patients with advanced non-small-cell
carcinoma of the lung (NSCLC) is controversial. To study this question, the National Cancer …

… We did not attempt to differentiate between synchronous primary lung cancers and
intrapulmonary metastases in this analysis. However, the incidence of multifocal lung cancer in this …

… Seventy‐one consecutive patients with small cell lung cancer (SCLC) were treated in the
Radiation Oncology Branch of the National Cancer Institute using six different radiation …

… small cell lung cancer) by … survival of patients with left lung non–small cell lung cancer and
metastases in only 1 of lymph node levels 5, 6, or 7 and right lung non–small cell lung cancer …

… Lung cancer is one of the most prevalent types of cancer, with an estimated 2.1 million new
… Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers [2] with …

… Patients who received modern systemic therapy for their LM (defined as erlotinib, gefitinib,
pemetrexed, bevacizumab, or crizotinib) had a prolonged survival with LM compared with …

This study aimed to identify predictive factors associated with prognostic benefits of gefitinib.
A total of 221 Japanese patients who received gefitinib (250 mg day− 1) were examined …